MiNK Therapeutics, Inc.

NasdaqCM:INKT Stock Report

Market Cap: US$58.1m

MiNK Therapeutics Future Growth

Future criteria checks 0/6

MiNK Therapeutics is forecast to grow earnings and revenue by 3.2% and 66.6% per annum respectively while EPS is expected to grow by 8.2% per annum.

Key information

3.2%

Earnings growth rate

8.23%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate66.6%
Future return on equityn/a
Analyst coverage

Low

Last updated18 May 2026

Recent future growth updates

Recent updates

New Narrative • Mar 05

Off The Shelf Cell Therapies Will Reshape Immunotherapy And Support A Long Term Opportunity

Catalysts About MiNK Therapeutics MiNK Therapeutics focuses on allogeneic invariant natural killer T cell therapies aimed at restoring immune balance in cancer, pulmonary disease and transplant settings. What are the underlying business or industry changes driving this perspective?
Analysis Article • Mar 05

MiNK Therapeutics, Inc.'s (NASDAQ:INKT) Intrinsic Value Is Potentially 18% Below Its Share Price

Key Insights The projected fair value for MiNK Therapeutics is US$6.68 based on 2 Stage Free Cash Flow to Equity MiNK...
Analysis Article • Oct 26

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jun 28

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Mar 18

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 16

MiNK Therapeutics GAAP EPS of -$0.18

MiNK Therapeutics press release (NASDAQ:INKT): Q2 GAAP EPS of -$0.18. Based on the Company’s current plans and projections, MiNK believes its cash and cash equivalents balance as of June 30, 2022 of $29.8M will be sufficient to satisfy its liquidity requirements for more than one year from when these financial statements were issued.
Seeking Alpha • Aug 09

MiNK Therapeutics GAAP EPS of -$0.18

MiNK Therapeutics press release (NASDAQ:INKT): Q2 GAAP EPS of -$0.18. The company ended the second quarter 2022 with a cash balance of $29.8 million as compared to $38.9 million at December 31, 2021.
Seeking Alpha • Jun 23

MiNK Therapeutics A Bargain For Potential Cell Therapies

iNKT cells have unique properties that could be therapeutic. MiNK Therapeutics has shown it can both manufacture and engineer iNKT cells. Preliminary data expected before year-end could push the stock price substantially higher.
Analysis Article • May 05

We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Earnings and Revenue Growth Forecasts

NasdaqCM:INKT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20282-24-24N/A2
12/31/2027N/A-16-16N/A2
12/31/2026N/A-12-8N/A2
3/31/2026N/A-12-6-6N/A
12/31/2025N/A-12-6-6N/A
9/30/2025N/A-12-6-6N/A
6/30/2025N/A-11-8-8N/A
3/31/2025N/A-10-8-8N/A
12/31/2024N/A-11-10-10N/A
9/30/2024N/A-14-11-11N/A
6/30/2024N/A-17-12-12N/A
3/31/2024N/A-21-14-14N/A
12/31/2023N/A-22-16-16N/A
9/30/2023N/A-25-17-17N/A
6/30/2023N/A-26-19-19N/A
3/31/2023N/A-26-19-19N/A
12/31/2022N/A-28-19-19N/A
9/30/2022N/A-26-16-16N/A
6/30/2022N/A-34-14-14N/A
3/31/2022N/A-34-13-13N/A
12/31/2021N/A-30-13-13N/A
9/30/2021N/A-26-13-13N/A
6/30/2021N/A-18-12-12N/A
3/31/2021N/A-16-11-11N/A
12/31/2020N/A-16-8-8N/A
12/31/20191-24N/A-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INKT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INKT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INKT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INKT is forecast to have no revenue next year.

High Growth Revenue: INKT is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if INKT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 07:58
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MiNK Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Kalpit PatelB. Riley Securities, Inc.
Maneka MirchandaneyEvercore ISI